top-left-banner

Saturday, Jan 31st

Last update02:11:08 PM GMT

TwitterLinkedinYoutubeGoogleFeed

Banner

User1

User2c

User3

You are here: BioMedTech

BioMedTech

Abcam CEO leads Horizon’s $29 million funding

Horizon Discovery CEO Darrin DisleyHorizon Discovery, the Cambridge UK business pioneering personalised medicines technology, has announced a final closing in a $29.1 million (£18.2m) funding round – led by Jonathan Milner, CEO of antibodies company Abcam plc.

Cannabis-based drugs firm surges into profit

GW Pharmaceuticals CEO Justin GoverGW Pharmaceuticals, the Cambridge UK medical technology business whose products are based on cannabis, has turned a 2012 first half loss into a 2013 H1 profit.

Cambridge sparks new era in cancer diagnostics

The revolutionary diagnosis and treatment solutionA new generation of cancer diagnostic devices has been launched through a medical technology alliance between UK business Cambridge Consultants and Singapore-based Clearbridge BioMedics.

Cambridge leads revolution in pharma analysis

 Dr Madhuri WarrenA company revolutionising pharmaceutical analysis is expanding its global influence from a new facility in the Cambridge UK technology cluster.

£24m obesity research boost for Cambridge

Professor Sir Leszek Borysiewicz, Vice-Chancellor of the University of Cambridge - “Obesity an urgent public health issue."The Medical Research Council and Wellcome Trust are investing £24 million into obesity research in the Cambridge UK medical technology cluster.

Pursuit steps up IP fire sale

PDX-ReactorThe stricken Cambridge UK technology company Pursuit Dynamics has battled hard to eliminate most of the liabilities associated with its PDX business and may wipe them all out by the end of June.

AstraZeneca picks BioMed Campus for HQ

The MRC LMB at Cambridge Biomedical CampusMedical technology pioneer AstraZeneca has chosen the Cambridge Biomedical Campus at the Addenbrooke’s Hospital site in Cambridge UK for its new global headquarters.

Phytopharm cash burn exposed

Phytopharm intends to come off the main London market and switch to AIMCambridge UK medical technology business Phytopharm reported an unaudited post-tax loss of £2.65 million for the six months to the end of March but it was the cash burn that evidenced the reasons for the company’s urgent restructuring.

Page 52 of 137